Table 2.
Comparison of T-SPOT.TB® and QFT results in patients with HTLV-1-positive rheumatic disease.
| Case | HTLV-1 infection status | Rheumatic disease | Spot count in T-SPOT.TB® assay panels | IFN-γ levels in QFT assay tubes (IU/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESAT-6 | CFP10 | Negative control |
Positive control |
Result | TB1 value | TB2 value | Nil value | Mitogen value |
Result | |||
| 1 | AC | SSc | 483 | 484 | 747 | 550 | Invalid | 0.56 | <0.05 | 7.98 | 3.78 | Negative |
| 2 | AC | RA | 479 | 606 | 661 | 695 | Invalid | 0.07 | <0.05 | 0.15 | >10.00 | Negative |
| 3 | HAM/TSP | RA | 55 | 47 | 244 | 590 | Invalid | 0.15 | 0.21 | 0.33 | >10.00 | Negative |
| 4 | AC | RA | 148 | 170 | 220 | 318 | Invalid | <0.05 | <0.05 | 0.09 | 9.61 | Negative |
| 5 | AC | DM | 174 | 149 | 209 | 591 | Invalid | <0.05 | <0.05 | 0.06 | >10.00 | Negative |
| 6 | ATL | SLE, SjS | 105 | 80 | 181 | 558 | Invalid | 0.51 | 0.21 | 1.98 | 7.82 | Positive |
| 7 | HAM/TSP, HU | RA, SjS | 69 | 115 | 133 | 263 | Invalid | <0.05 | <0.05 | <0.05 | 9.21 | Negative |
| 8 | ATL | SSc, SjS | 81 | 90 | 81 | 382 | Invalid | 0.15 | 0.06 | 0.41 | >10.00 | Negative |
| 9 | AC | RA | 48 | 44 | 73 | 208 | Invalid | <0.05 | <0.05 | 0.11 | >10.00 | Negative |
| 10 | AC | RA, SjS | 50 | 45 | 58 | 537 | Invalid | <0.05 | <0.05 | 0.09 | 5.88 | Negative |
| 11 | AC | SSc | 34 | 21 | 53 | 556 | Invalid | 0.13 | 0.15 | 0.26 | >10.00 | Negative |
| 12 | AC | GPA | 12 | 20 | 33 | 299 | Invalid | <0.05 | <0.05 | <0.05 | 4.25 | Negative |
| 13 | AC | SjS | 0 | 0 | 18 | 284 | Invalid | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 14 | HAM/TSP | RA | 6 | 3 | 10 | 35 | Negative | <0.05 | 0.14 | 0.2 | >10.00 | Negative |
| 15 | AC | RS3PE | 11 | 8 | 10 | 77 | Negative | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 16 | AC | SSc | 6 | 5 | 6 | 297 | Negative | <0.05 | <0.05 | 0.05 | >10.00 | Negative |
| 17 | AC | RA, SjS | 2 | 0 | 4 | 334 | Negative | <0.05 | <0.05 | 0.06 | >10.00 | Negative |
| 18 | AC | RA | 2 | 7 | 3 | 286 | Negative | <0.05 | <0.05 | 0.12 | >10.00 | Negative |
| 19 | AC | SjS | 2 | 2 | 2 | 854 | Negative | <0.05 | <0.05 | 0.07 | >10.00 | Negative |
| 20 | AC | RA | 0 | 0 | 1 | 234 | Negative | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 21 | AC | DM | 4 | 2 | 0 | 79 | Negative | <0.05 | <0.05 | <0.05 | 0.67 | Negative |
| 22 | AC | RA | 0 | 0 | 0 | 103 | Negative | <0.05 | <0.05 | 0.09 | >10.00 | Negative |
| 23 | AC | DM | 0 | 0 | 0 | 91 | Negative | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 24 | AC | RA | 0 | 0 | 0 | 122 | Negative | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 25 | AC | RA | 0 | 0 | 0 | 378 | Negative | <0.05 | <0.05 | <0.05 | 6.76 | Negative |
| 26 | AC | RA | 0 | 2 | 0 | 113 | Negative | <0.05 | <0.05 | 0.18 | >10.00 | Negative |
| 27 | AC | RA | 0 | 0 | 0 | 408 | Negative | <0.05 | <0.05 | 0.08 | >10.00 | Negative |
| 28 | AC | RA, SjS | 0 | 0 | 0 | 305 | Negative | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 29 | AC | RA | 0 | 0 | 0 | 504 | Negative | <0.05 | <0.05 | 0.06 | >10.00 | Negative |
| 30 | AC | RA, SjS | 0 | 0 | 0 | 71 | Negative | <0.05 | <0.05 | <0.05 | >10.00 | Negative |
| 31 | AC | RA | 0 | 0 | 0 | 230 | Negative | <0.05 | <0.05 | <0.05 | 6.66 | Negative |
| 32 | AC | RA, SjS | 0 | 0 | 0 | 66 | Negative | <0.05 | <0.05 | 0.05 | 0.62 | Negative |
| 33 | AC | SLE | 0 | 0 | 0 | 155 | Negative | <0.05 | <0.05 | <0.05 | 2.18 | Negative |
ESAT-6, early secretary antigen target 6; CFP10, culture filtrate protein 10; AC, asymptomatic carrier; ATL, adult T-cell leukemia lymphoma; HAM/TSP, HTLV-1-associated myelopathy/tropic spastic paraparesis; HU, HTLV-1 associated uveitis; RA, rheumatoid arthritis; DM, dermatomyositis; SLE, systemic lupus erythematosus; SjS, Sjögren’s syndrome; SSc, systemic scleroderma; GPA, granulomatosis polyangiitis; RS3PE, remitting seronegative symmetrical synovitis with pitting edema syndrome.